Fraxiparine

Fraxiparine

nadroparin

Manufacturer:

Aspen Pharmacare Asia

Distributor:

Cordial Trading
/
Primal
Concise Prescribing Info
Contents
Nadroparin Ca
Dosage/Direction for Use
General prophylaxis of thromboembolic disorders 0.3 mL SC daily for at least 7 days. Prophylaxis of thromboembolism in orthopaedic surgery Initially 12 hr pre-op & 12 hr post-op. These & subsequent once-daily doses should be adjusted based on body wt. Treatment should continue for at least 10 days. Patient >70 kg 0.4 mL pre-op to day 3, 0.6 mL day 4 onwards; 51-70 kg 0.3 mL pre-op to day 3, 0.4 mL day 4 onwards <51 kg 0.2 mL pre-op to day 3, 0.3 mL day 4 onwards. Treatment of thromboembolic disorders Administer 12 hrly SC dose based on body wt for a usual 10 days. Patient ≥100 kg 1 mL, 90-99 kg 0.9 mL, 80-89 kg 0.8 mL, 70-79 kg 0.7 mL, 60-69 kg 0.6 mL, 50-59 kg 0.5 mL, 40-49 kg 0.4 mL. Treatment of unstable angina & non-Q wave MI Administer 12 hrly SC dose based on body wt for around 6 days up to clinical stabilization. Patient ≥100 kg 1 mL, 90-99 kg 0.9 mL, 80-89 kg 0.8 mL, 70-79 kg 0.7 mL, 60-69 kg 0.6 mL, 50-59 kg 0.5 mL, <50 kg 0.4 mL. The same vol of initial IV bolus dose must be given. Prevention of clotting during haemodialysis To be given as a single dose into arterial line at the start of each session. Patient >70 kg 0.6 mL, 51-70 kg 0.4 mL, <51 kg 0.3 mL.
Contraindications
Hypersensitivity to nadroparin or any excipients of Fraxiparine. History of thrombocytopenia w/ nadroparin. Active bleeding or increased risk of haemorrhage in relation w/ haemostasis disorders except for disseminated intravascular coagulation not induced by heparin, organic lesion likely to bleed, haemorrhagic CVA, acute infectious endocarditis. Severe renal impairment (CrCl <30 mL/min), in patients receiving treatment for thromboembolic disorders, unstable angina & non-Q wave MI.
Special Precautions
Cutaneous necrosis. Monitor platelet count throughout the course of treatment, plasma K in patients at risk of hyperkalaemia, signs & symptoms of neurological impairment. Discontinue if thrombocytopenia occurs. Hepatic failure, severe arterial HTN, history of peptic ulceration or organic lesion likely to bleed, vascular chorioretinal disorder; post-op brain, spinal cord or eye surgery. Increased risk of bleeding in patients w/ renal impairment. Caution w/ spinal/epidural anesth/spinal puncture & concomitant drugs. Use w/ salicylates, NSAIDs & antiplatelet drugs. Latex allergy. Pregnancy & lactation. Childn & adolescent <18 yr. Elderly.
Adverse Reactions
Haemorrhagic manifestations, small haematoma at the inj site, inj site reaction, elevated transaminases. Rarely, thrombocytopenia (including heparin-induced thrombocytopenia), calcinosis at the inj site, eosinophilia, hypersensitivity reactions, reversible hyperkalaemia, priapism, cutaneous necrosis usually occuring at the inj site. Rash, urticaria, erythema, pruritus.
Drug Interactions
Oral anticoagulants, systemic (gluco-) corticosteroids & dextrans.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AB06 - nadroparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.
Presentation/Packing
Form
Fraxiparine inj 2850 AXa iu/0.3 mL
Packing/Price
10 × 1's
Form
Fraxiparine inj 3800 AXa iu/0.4 mL
Packing/Price
10 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in